CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Iguratimod

艾拉莫德 杂质对照品Iguratimod Impurities

40 个杂质条目40 impurity entries

本页汇总 艾拉莫德 的 40 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 40 impurity reference standards of Iguratimod. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 艾拉莫德(Iguratimod)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStability-indicating study of iguratimod: isolation and characterization of a potential degradant using preparative HPLC-MS, LC-HRMS, and NMR techniques
    Analytical methods : advancing methods and applications · 2026 · Gore P et al.  ·  PMID 41400101  ·  DOI
  2. 分析方法Analytical MethodsSimultaneous determination of iguratimod and its metabolite in rat plasma using a UPLC-MS/MS method: Application for drug-drug interaction
    Journal of pharmaceutical and biomedical analysis · 2024 · Shi L et al.  ·  PMID 38471255  ·  DOI
  3. 分析方法Analytical MethodsPreparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma
    Iranian journal of pharmaceutical research : IJPR · 2019 · Han JP et al.  ·  PMID 31531047  ·  DOI
  4. 分析方法Analytical MethodsA rapid and sensitive LC-MS/MS method for analysis of iguratimod in human plasma: Application to a pharmacokinetic study in Chinese healthy volunteers
    Biomedical chromatography : BMC · 2018 · Xia Y et al.  ·  PMID 29729125  ·  DOI
  5. 分析方法Analytical MethodsDetermination of iguratimod in rat plasma by high performance liquid chromatography: method and application
    Biomedical chromatography : BMC · 2008 · Zhou T et al.  ·  PMID 17939167  ·  DOI

艾拉莫德 —— 原料药与杂质对照品Iguratimod — drug substance & impurities

共 41 个条目(含原料药本体)41 items incl. the drug substance
Iguratimod structure
原料药 APIAPI
艾拉莫德Iguratimod
Iguratimod
CAS No.123663-49-0
Chemical FormulaC17H14N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 2 structure
2
艾拉莫德杂质2Iguratimod Impurity 2
Iguratimod Impurity 2
CAS No.84594-95-6
Chemical FormulaC13H11NO4
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 3 structure
3
艾拉莫德杂质3Iguratimod Impurity 3
Iguratimod Impurity 3
CAS No.76838-72-7
Chemical FormulaC13H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 5 structure
5
艾拉莫德杂质5Iguratimod Impurity 5
Iguratimod Impurity 5
CAS No.1179354-65-4
Chemical FormulaC18H16N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 6 structure
6
艾拉莫德杂质6Iguratimod Impurity 6
Iguratimod Impurity 6
CAS No.149457-03-4
Chemical FormulaC16H16N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 7 structure
7
艾拉莫德杂质7Iguratimod Impurity 7
Iguratimod Impurity 7
CAS No.149456-98-4
Chemical FormulaC17H18N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 8 structure
8
艾拉莫德杂质8Iguratimod Impurity 8
Iguratimod Impurity 8
CAS No.123664-84-6
Chemical FormulaC14H15NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 11 Monomer structure
11
艾拉莫德杂质11 单体Iguratimod Impurity 11 Monomer
Iguratimod Impurity 11 Monomer
CAS No.150831-14-4
Chemical FormulaC15H16N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 12 structure
12
艾拉莫德杂质12Iguratimod Impurity 12
Iguratimod Impurity 12
CAS No.544482-14-6
Chemical FormulaC18H18N2O7S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 13 structure
13
艾拉莫德杂质13Iguratimod Impurity 13
Iguratimod Impurity 13
CAS No.123663-50-3
Chemical FormulaC18H16N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 15 structure
15
艾拉莫德杂质15Iguratimod Impurity 15
Iguratimod Impurity 15
CAS No.18300-37-3
Chemical FormulaC2H8N2O4S2
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 17 structure
17
艾拉莫德杂质17Iguratimod Impurity 17
Iguratimod Impurity 17
CAS No.109-82-0
Chemical FormulaC3H4N2
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 19 Monomer structure
19
艾拉莫德杂质19 单体Iguratimod Impurity 19 Monomer
Iguratimod Impurity 19 Monomer
CAS No.123663-48-9
Chemical FormulaC16H14N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 30 structure
30
艾拉莫德杂质30Iguratimod Impurity 30
Iguratimod Impurity 30
CAS No.10298-80-3
Chemical FormulaC7H6ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 32 structure
32
艾拉莫德杂质32Iguratimod Impurity 32
Iguratimod Impurity 32
CAS No.16156-59-5
Chemical FormulaC7H8O3S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 33 structure
33
艾拉莫德杂质33Iguratimod Impurity 33
Iguratimod Impurity 33
CAS No.149436-41-9
Chemical FormulaC16H18N2O5S·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 33 Monomer structure
33
艾拉莫德杂质33 单体Iguratimod Impurity 33 Monomer
Iguratimod Impurity 33 Monomer
CAS No.759430-03-0
Chemical FormulaC16H18N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 39 structure
39
艾拉莫德杂质39Iguratimod Impurity 39
Iguratimod Impurity 39
CAS No.116289-67-9
Chemical FormulaC13H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 40 structure
40
艾拉莫德杂质40Iguratimod Impurity 40
Iguratimod Impurity 40
CAS No.791108-77-5
Chemical FormulaC13H11NO4
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 42 structure
42
艾拉莫德杂质42Iguratimod Impurity 42
Iguratimod Impurity 42
CAS No.2578085-65-9
Chemical FormulaC14H13NO6S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 44 structure
44
艾拉莫德杂质44Iguratimod Impurity 44
Iguratimod Impurity 44
CAS No.2375563-22-5
Chemical FormulaC15H17NO6S2
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 50 structure
50
艾拉莫德杂质50Iguratimod Impurity 50
Iguratimod Impurity 50
CAS No.123664-52-8
Chemical FormulaC15H15NO5S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 51 structure
51
艾拉莫德杂质51Iguratimod Impurity 51
Iguratimod Impurity 51
CAS No.123662-92-0
Chemical FormulaC18H16N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 52 structure
52
艾拉莫德杂质52Iguratimod Impurity 52
Iguratimod Impurity 52
CAS No.149456-97-3
Chemical FormulaC18H20N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 53 structure
53
艾拉莫德杂质53Iguratimod Impurity 53
Iguratimod Impurity 53
CAS No.149457-04-5
Chemical FormulaC17H18N2O6S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 54 structure
54
艾拉莫德杂质54Iguratimod Impurity 54
Iguratimod Impurity 54
CAS No.2401-24-3
Chemical FormulaC7H8ClNO
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 54 Hydrochloride structure
54
艾拉莫德杂质54 盐酸盐Iguratimod Impurity 54 Hydrochloride
Iguratimod Impurity 54 Hydrochloride
CAS No.85006-21-9
Chemical FormulaC7H8ClNO·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 55 structure
55
艾拉莫德杂质55Iguratimod Impurity 55
Iguratimod Impurity 55
CAS No.98446-54-9
Chemical FormulaC7H7BrClNO
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 56 structure
56
艾拉莫德杂质56Iguratimod Impurity 56
Iguratimod Impurity 56
CAS No.1263376-85-7
Chemical FormulaC7H7BrClNO
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 64 structure
64
艾拉莫德杂质64Iguratimod Impurity 64
Iguratimod Impurity 64
CAS No.544482-16-8
Chemical FormulaC17H16N2O7S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 79 structure
79
艾拉莫德杂质79Iguratimod Impurity 79
Iguratimod Impurity 79
CAS No.10265-97-1
Chemical FormulaC7H5ClN2O5
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 80 structure
80
艾拉莫德杂质80Iguratimod Impurity 80
Iguratimod Impurity 80
CAS No.1340086-28-3
Chemical FormulaC8H10ClNO3S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 93 structure
93
艾拉莫德杂质93Iguratimod Impurity 93
Iguratimod Impurity 93
CAS No.84594-96-7
Chemical FormulaC12H9NO4
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 99 structure
99
艾拉莫德杂质99Iguratimod Impurity 99
Iguratimod Impurity 99
CAS No.76838-77-2
Chemical FormulaC12H11NO2
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 100 Monomer structure
100
艾拉莫德杂质100 单体Iguratimod Impurity 100 Monomer
Iguratimod Impurity 100 Monomer
CAS No.3079355-61-3
Chemical FormulaC16H18N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 100 structure
100
艾拉莫德杂质100Iguratimod Impurity 100
Iguratimod Impurity 100
CAS No.3079355-62-4
Chemical FormulaC16H18N2O5S·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 107 structure
107
艾拉莫德杂质107Iguratimod Impurity 107
Iguratimod Impurity 107
CAS No.89-21-4
Chemical FormulaC7H6ClNO3
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 114 structure
114
艾拉莫德杂质114Iguratimod Impurity 114
Iguratimod Impurity 114
CAS No.1182747-05-2
Chemical FormulaC15H13NO5
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 120 structure
120
艾拉莫德杂质120Iguratimod Impurity 120
Iguratimod Impurity 120
CAS No.51230-16-1
Chemical FormulaC13H11NO4
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 121 structure
121
艾拉莫德杂质121Iguratimod Impurity 121
Iguratimod Impurity 121
CAS No.733729-21-0
Chemical FormulaC13H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Iguratimod Impurity 128 structure
128
艾拉莫德杂质128Iguratimod Impurity 128
Iguratimod Impurity 128
CAS No.51765-75-4
Chemical FormulaC14H14N2O6S
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

艾拉莫德 —— 研究文献与合成路线Iguratimod — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 艾拉莫德 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Iguratimod. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability-indicating study of iguratimod: isolation and characterization of a potential degradant using preparative HPLC-MS, LC-HRMS, and NMR techniques
    Gore P, Maykar D, Maity A, et al. · Analytical methods : advancing methods and applications · 2026 · 被引 1cited 1

合成与制备工艺专利Synthesis & process patents

  1. Iguratimod osmotic pump controlled slow-release preparation
    XIAOQIANG LI, TAO PENG, XIANGYANG XU, CHUNHUI LIU · 公开号 CN101564382CN101564382 · 2009
  2. Iguratimod derivatives, preparation method thereof and pharmaceutical use thereof
    XIHONG YANG · 公开号 CN101597271CN101597271 · 2009
  3. Sodium salt compound of Iguratimod, preparation method thereof and pharmaceutical use thereof
    XIHONG YANG · 公开号 CN101597272CN101597272 · 2009

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

艾拉莫德 杂质谱研究要点Iguratimod — impurity profiling notes

下面这些是拿到 艾拉莫德 的 41 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 41 impurity entries for Iguratimod, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances